NorthWest Biotherapeutics Inc (NWBO)

[biosectinvestor]

It was not a "Halt", it was a partial halt, and not for safety. Likely for the fact that crossover was so broad, likely owing to the fact that patients saw the treatment as very successful for their peers, that there was no longer a placebo arm and enrolling new placebo patients would be unethical. That would not prevent a trial from proceeding on to approval from any regulator, and especially not when a regular wanted the crossover to address risks that turned out to be non-existent.